Brokers Set Expectations for Edwards Lifesciences Co.’s FY2025 Earnings (NYSE:EW)
Edwards Lifesciences Co. (NYSE:EW – Get Rating) – Investment analysts at Jefferies Financial Group issued their FY2025 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a research note issued on Wednesday, April 26th. Jefferies Financial Group analyst M. Taylor forecasts that the medical research company will post earnings per share of $3.30 for the year. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.54 per share.
EW has been the subject of a number of other reports. TheStreet raised Edwards Lifesciences from a “c+” rating to a “b-” rating in a research note on Wednesday, April 19th. Sanford C. Bernstein lowered Edwards Lifesciences from an “outperform” rating to an “underperform” rating and decreased their target price for the company from $95.00 to $66.00 in a research report on Tuesday, January 31st. Citigroup lifted their target price on Edwards Lifesciences from $92.00 to $97.00 and gave the company a “buy” rating in a research report on Monday, April 3rd. Raymond James lowered Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Monday, February 6th. Finally, Mizuho boosted their price target on Edwards Lifesciences from $85.00 to $95.00 in a research report on Tuesday, April 25th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus target price of $89.42.
Edwards Lifesciences Price Performance
Shares of Edwards Lifesciences stock opened at $87.98 on Monday. The stock has a market cap of $53.32 billion, a price-to-earnings ratio of 36.51, a price-to-earnings-growth ratio of 5.00 and a beta of 1.02. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.17 and a current ratio of 3.01. The stock has a 50 day moving average price of $81.49 and a 200-day moving average price of $78.39. Edwards Lifesciences has a one year low of $67.13 and a one year high of $110.10.
Edwards Lifesciences (NYSE:EW – Get Rating) last announced its earnings results on Wednesday, April 26th. The medical research company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.39 billion. Edwards Lifesciences had a return on equity of 25.81% and a net margin of 27.07%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.60 EPS.
Insider Transactions at Edwards Lifesciences
In other news, VP Donald E. Bobo, Jr. sold 6,725 shares of the company’s stock in a transaction dated Monday, February 6th. The stock was sold at an average price of $80.75, for a total value of $543,043.75. Following the sale, the vice president now owns 62,561 shares in the company, valued at $5,051,800.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Donald E. Bobo, Jr. sold 6,725 shares of the company’s stock in a transaction dated Monday, February 6th. The stock was sold at an average price of $80.75, for a total value of $543,043.75. Following the sale, the vice president now owns 62,561 shares in the company, valued at $5,051,800.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Robert W.A. Sellers sold 12,270 shares of the company’s stock in a transaction dated Friday, April 28th. The stock was sold at an average price of $87.20, for a total value of $1,069,944.00. Following the completion of the transaction, the senior vice president now directly owns 11,750 shares of the company’s stock, valued at approximately $1,024,600. The disclosure for this sale can be found here. Insiders have sold 110,091 shares of company stock worth $8,819,677 over the last quarter. 1.29% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Edwards Lifesciences
Large investors have recently bought and sold shares of the business. Bogart Wealth LLC acquired a new position in Edwards Lifesciences in the 3rd quarter worth about $25,000. Core Alternative Capital raised its holdings in shares of Edwards Lifesciences by 96.1% during the first quarter. Core Alternative Capital now owns 353 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 173 shares during the last quarter. Trifecta Capital Advisors LLC acquired a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $28,000. Addison Advisors LLC raised its holdings in shares of Edwards Lifesciences by 708.0% during the fourth quarter. Addison Advisors LLC now owns 404 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 354 shares during the last quarter. Finally, MCF Advisors LLC raised its holdings in shares of Edwards Lifesciences by 179.6% during the first quarter. MCF Advisors LLC now owns 411 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 264 shares during the last quarter. Institutional investors and hedge funds own 80.35% of the company’s stock.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Edwards Lifesciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Edwards Lifesciences wasn’t on the list.
While Edwards Lifesciences currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
